Interaction of antibodies with liposomes bearing fluorescent haptens

Petrossian, Ashot; Owicki, John C.

doi:10.1016/0005-2736(84)90211-6

Cited by 38 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For liposomes with 10 times less antigen (0.1% biotin), the estimated distance between antigens is 24 nm (assuming 68,000 lipid molecules in the outer leaflet of a 100-nm liposome; Hutchinson et al, 1989), a distance still possible for bivalent binding assuming the hinge region of the antibody is flexible (Amzel and Poljak, 1979;Alzari et al, 1988). However, considering antigen lateral mobility in the bilayer, and that not all liposomal haptens are in a conformation available for binding (Petrossian and Owicki, 1984), bivalent binding would be less for liposomes with a much lower antigen density. This may be the reason for the large difference in antibody consumption between liposomes with 1% biotin and 0.1% biotin observed in the current study (Fig.…”

Section: Discussionmentioning

confidence: 99%

Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids

Li¹,

Mayer²,

Bally³

2002

J Pharmacol Exp Ther

View full text Add to dashboard Cite

One of the major obstacles in the development of ligandtargeted liposomes is poor liposome circulation longevity as a result of antibody-mediated elimination of these highly immunogenic carriers. Because studies from our laboratory suggest that it is not possible to reduce the immunogenicity of ligandconjugated liposomes by using surface-grafted poly(ethylene glycol) (PEG), we investigated the usefulness of PEG in protecting hapten-conjugated liposomes from elimination by an existing immune response that was previously established against the hapten. Using biotin as a model hapten, a strong biotinspecific antibody response was generated in mice by using bovine serum albumin-biotin. When these animals were challenged with liposomes containing biotin-conjugated lipid (1 or 0.1%), these liposomes were rapidly eliminated. Incorporation of PEG-lipids into these liposomes substantially reduced biotinspecific antibody binding as measured using an in vitro antibody consumption assay. However, depending on the hapten concentration, significant reductions in antibody binding through the use of PEG-lipids may not be sufficient to protect these liposomes from rapid elimination in vivo. Complete protection of liposomes was only achieved when the biotin concentration on liposome surface was low (0.1%) and with 5 mol% of either 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] or 1,2-dipalmatoyl-sn-glycero-3-phosphoethanolamine-n-methoxy(polyethylene glycol)-2000]. The use of 1,2-dimyristoyl-sn-glycero-3-phosphoethanolamine-n-[methoxy(polyethylene glycol)-2000] (up to 15 mol%) was not effective in protecting liposomes from rapid elimination in vivo, indicating the limited usefulness of this highly exchangeable PEG-lipid. In conclusion, our in vivo and in vitro data indicate that liposomes can be protected from antibody-mediated elimination by using the right type and concentration of PEG-lipids. This result has important implication in the development of ligand-targeted liposomes.Active targeting can be achieved by conjugating macromolecules such as antibodies, peptides, and ligands of natural receptors onto liposome surfaces to improve the specificity of these drug carriers to disease sites (Vingerhoeds et al., 1994). Although active targeting of liposomes has met with some success both in vitro and in vivo (Park et al., 1995;Kirpotin et al., 1997;Gabizon et al., 1999), further development of ligand-targeted liposomes for in vivo use remains a challenge due to the immunogenicity of the drug carriers bearing surface ligands that function as antigenic haptens (Phillips and Emili, 1991;Phillips et al., 1994;Phillips and Dahman, 1995). Repeated administration of these liposomes becomes problematic because the pharmacokinetic and biodistribution behaviors of the carrier change after subsequent injections of the drug carrier (Shek and Heath, 1983;Phillips and Emili, 1991;Phillips et al., 1994;Harding et al., 1997;Tardi et al., 1997;Dams et al., 2000). Enhanced elimination of the liposomes...

show abstract

Section: Discussionmentioning

confidence: 99%

Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids

Li¹,

Mayer²,

Bally³

2002

J Pharmacol Exp Ther

View full text Add to dashboard Cite

show abstract

“…4. Since the rate and strength of the antigen-antibody binding depended on the lipid composition of the vesicles, 11,18) it was apparent that binding was favorable in that membrane.…”

Section: Discussionmentioning

confidence: 99%

“…4, as reported elsewhere. 11,[17][18][19] The relative rate of immunolysis (% release/min) was in the order of II > cholesterol > I >0> III-VI at every molar ratio except for a slightly rise with analogue 0 at molar ratios above 1.0. Increased incorporation of analogue generally resulted in a reduction of the rate of immunolysis except for analogue II, for which the rate remained nearly unchanged up to 1.00 molar addition and decreased slowly above that amount.…”

Section: Effect Of Incorporation Of Analogue II On Antibody-dependentmentioning

confidence: 93%

Alteration of immunolysis reaction on liposome membrane by various cholesterol analogues.

Glagasigij

Satô

Suzuki

1988

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Complement-mediatedimmunolysis was employed to examine the effect of incorporation of various cholesterol analogues, having a terminal hydroxyl group or terminal primary amine group at the 3-position of the cholestene nucleus, into the bilayer membrane of haptenated reverse-phase evaporationvesicles. An enhancement of immunolysis was observed when triethoxycholesterol (analogue II) was incorporated, while no measurable change was detected when the chain length of the substituted groups in hydroxy cholesterols was shorter than that of analogue II. However, for amino cholesterol analogues, a remarkable decrease in immunolysis was seen. These results may arise from changes of membrane properties such as bilayer fluidity, lateral hapten mobility and complement fixation.

show abstract

“…A large number of naturally occurring antibody-antigen interactions involve such recognition and selective binding. Immunogenic responses associated with natural cell membranes have motivated various investigations including studies of artificial lipid membranes [l, 2] either in the form of vesicles [3][4][5][6], or as membranes supported on solid substrates for the development of immunosensors [7][8][9][10][11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Rapid Flow Injection Electrochemical Detection of Arochlor 1242 Using Stabilized Lipid Membranes with Incorporated Sheep anti‐PCB Antibody

et al. 2011

View full text Add to dashboard Cite

This work describes a novel electrochemical biosensor based on a supported polymerized lipid film with incorporated Sheep anti-PCB antibody for the rapid detection of arochlor 1242 in flowing solution streams. The antibody was incorporated into the lipid film during polymerization. Injections of antigen were made into flowing streams of a carrier electrolyte solution. Experiments were done in a stopped-flow mode using lipid mixtures containing 15 % (w/w) dipalmitoylphosphatidic acid (DPPA) to provide only a single transient current signal with a magnitude related to the antigen concentration. Lipid films containing 35 % DPPA were used to examine regeneration of the active sites of antibody after complex formation by washing with the carrier electrolyte solution. Repetitive cycles of injection of antigen have shown that the maximum number of cycles is about 5.

show abstract

Interaction of antibodies with liposomes bearing fluorescent haptens

Cited by 38 publications

References 41 publications

Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids

Prevention of Antibody-Mediated Elimination of Ligand-Targeted Liposomes by Using Poly(Ethylene glycol)-Modified Lipids

Alteration of immunolysis reaction on liposome membrane by various cholesterol analogues.

Rapid Flow Injection Electrochemical Detection of Arochlor 1242 Using Stabilized Lipid Membranes with Incorporated Sheep anti‐PCB Antibody

Contact Info

Product

Resources

About